JGC
ELOS

J. Goldman & Co’s Syneron Medical Ltd ELOS Stock Holding History

J. Goldman & Co’s Portfolio ELOS Stock Details ELOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-325,000
Closed -$2.32M – 329
2015
Q3 		$2.32M Buy
325,000
+240,488
+285% +$2.31M 0.2% 132
2015
Q2 		$898K Buy
+84,512
New +$990K 0.05% 192

Other funds holding ELOS

SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DGHMC
Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

J. Goldman & Co's ELOS Position: Q4 2015 in Review

J. Goldman & Co sold out of Syneron Medical Ltd (ELOS) in Q4 2015, closing a stake of 325,000 shares — an estimated $2.32M sold.

J. Goldman & Co first reported a position in ELOS in Q2 2015 and held it in 2 quarters. The position peaked at $2.32M in Q3 2015. 57 funds tracked by Wall St. Rank hold ELOS as of Q4 2015.

  • J. Goldman & Co reported no remaining Syneron Medical Ltd position as of Q4 2015 after selling out during the quarter.
  • J. Goldman & Co sold 325,000 Syneron Medical Ltd shares in Q4 2015, an estimated $2.32M.
  • J. Goldman & Co first reported a position in Syneron Medical Ltd in Q2 2015 and held it in 2 quarters.
  • J. Goldman & Co's Syneron Medical Ltd position peaked at $2.32M in Q3 2015.
  • 57 funds tracked by Wall St. Rank held Syneron Medical Ltd as of Q4 2015.

Based on J. Goldman & Co's 13F filing for Q4 2015, filed 10 Feb 2016.